Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals
- 24 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 26 (13) , 1707-1717
Abstract
Objective: To evaluate the change in categories of risk of death by adding D-dimer to conventional mortality risk factors. Design: Cohort study. Methods: Data on HIV-infected participants receiving standard combination antiretroviral therapy in two clinical trials (Evaluation of Subcutaneous Proleukin in a Randomized International Trial and Strategic Management of antiretroviral therapy), who had baseline D-dimer measured, were randomly split into two equal training and a validation datasets. A multivariable survival model was built using the training dataset and included only conventional mortality risk factors measured at baseline. D-dimer was added to create the comparison model. The level of reclassification of mortality risk, for those with at least 5-years of follow-up, was then assessed by tabulating mortality risk defined as low (≤2% predicted rate), moderate (2–5%) or high (>5%). Reclassification analyses were then repeated on the validation dataset. Results: The analysis population at baseline had a mean age of 43 years, median CD4+ cell count of 535 cells/μl (IQR: 420–712), and 83% had HIV RNA of at least 500 copies/ml. In the training dataset (n = 1946, 8939 person-years), there were 83 deaths at a rate of 0.93 per 100 person-years. Addition of D-dimer to the reference model resulted in 6% or fewer (P > 0.05) being correctly reassigned, either up or down, to a new risk category, in both, training and validation datasets. The integrated discrimination improvement in training and validation datasets was 0.60% (P = 0.084) and 0.45% (P = 0.168), respectively. Conclusion: In this relatively well population, at the given risk cutoffs, D-dimer appeared to only modestly improve the discernment of risk. Risk reclassification provides a method for assessing the clinical utility of biomarkers in HIV cohort studies.Keywords
This publication has 41 references indexed in Scilit:
- Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strataAIDS, 2011
- Changing Predictors of Mortality Over Time From cART StartJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs StudyEuropean Journal of Preventive Cardiology, 2010
- Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in EuropeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Low CD4+T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient StudyClinical Infectious Diseases, 2010
- Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAIDS, 2010
- Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkersHIV Medicine, 2010
- CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infectionAIDS, 2008
- Mortality in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003HIV Medicine, 2005